Molecular markers and clinical behavior of uterine carcinosarcomas: Focus on the epithelial tumor component

Modern Pathology

Volumn 24, Issue 10, 2011, Pages 1368-1379

  De Jong, Renske A ^a   Nijman, Hans W ^a   Wijbrandi, Tera F ^a   Reyners, Anna K L ^a   Boezen, H Marike ^a   Hollema, Harry ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

carcinogenesis; clinical behavior; epithelial component; immunohistochemistry; uterine carcinosarcomas

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOSARCOMA; CHONDROSARCOMA; CHROMOSOME 10; CLINICAL ARTICLE; COHORT ANALYSIS; ENDOMETRIUM SARCOMA; EPITHELIUM TUMOR; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MICROARRAY ANALYSIS; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SALPINGOOOPHORECTOMY; UTERINE CARCINOSARCOMA; UTERUS CANCER;

AGED; CARCINOSARCOMA; CHI-SQUARE DISTRIBUTION; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 80053560060     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.88     Document Type: Article

References (42)

1. Brooks SE, Zhan M, Cote T, et al. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol 2004;93:204-208. (Pubitemid 38429571)
2. Lax SF. Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium. Pathology 2007;39:46-54.
3. Samarnthai N, Hall K, Yeh IT. Molecular profiling of endometrial malignancies. Obstet Gynecol Int 2010; Article ID 162363.
4. McCluggage WG, Abdulkader M, Price JH, et al. Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases. Int J Gynecol Cancer 2000;10:280-284.
5. Silverberg SG, Major FJ, Blessing JA, et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990;9:1-19. (Pubitemid 20067452)
6. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002;12:687-690. (Pubitemid 35388035)
7. McCluggage WG, Robboy SJ. Mesenchymal uterine tumors and adenomyosis. In: Robboy SJ, Mutter GL, Prat J, Bentley RC, Russell P, Anderson MC (eds). Pathology of the Female Reproductive Tract, 2 edn. Churchill Livingstone Elsevier: Amsterdam, 2009, pp 427-456.
8. Kounelis S, Jones MW, Papadaki H, et al. Carcinosarcomas (malignant mixed Mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol 1998;29:82-87. (Pubitemid 28049550)
9. Wada H, Enomoto T, Fujita M, et al. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res 1997;57:5379-5385. (Pubitemid 27516377)
10. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-17. (Pubitemid 13194678)
11. Amant F, Cadron I, Fuso L, et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol 2005;98:274-280. (Pubitemid 41019116)
12. George E, Lillemoe TJ, Twiggs LB, et al. Malignant mixed Mullerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival. Int J Gynecol Pathol 1995;14:39-44.
13. D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol 2010;116:131-139.
14. Homesley HD, Filiaci V, Markman M, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:526-531. (Pubitemid 350002959)
15. Powell MA, Filiaci VL, Rose PG, et al. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol 2010;28: 2727-2731.
16. Wolfson AH, Brady MF, Rocereto T, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 2007;107:177-185. (Pubitemid 47575740)
17. FIGO Cancer Committee. Staging Announcement: FIGO Cancer Committee. Cancer Committee of the International Federation of Gynaecology and Obstetrics (1986). Gynecol Oncol 2008;25:383-385.
18. Silverberg SG, Kurman RJ, Nogales F, et al. Tumours of the uterine corpus. In: Tavassoli FA, Devilee P (eds). Pathology and Genetics of Tumours of the Breast and Female Genital Organs (World Health Organization Classification of Tumours) 1st edn. IARC Press: Lyon, 2003, pp 217-257.
19. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847. (Pubitemid 28331029)
20. Noordhuis MG, Eijsink JJ, ten Hoor KA, et al. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res 2009;15:7389-7397.
21. Taylor NP, Zighelboim I, Huettner PC, et al. DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. Mod Pathol 2006;19:1333-1338. (Pubitemid 44423080)
22. Niessen RC, Berends MJ, Wu Y, et al. Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer. Gut 2006;55:1781-1788. (Pubitemid 44893579)
23. Abargel A, Avinoach I, Kravtsov V, et al. Expression of p27 and p53: comparative analysis of uterine carcinosarcoma and endometrial carcinoma. Int J Gynecol Cancer 2004;14:354-359. (Pubitemid 38533909)
24. Saegusa M, Hashimura M, Kuwata T, et al. Requirement of the Akt/beta-catenin pathway for uterine carcinosarcoma genesis, modulating E-cadherin expression through the transactivation of slug. Am J Pathol 2009;174:2107-2115.
25. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268-1274.
26. Ansink AC, Cross PA, Scorer P, et al. The hormonal receptor status of uterine carcinosarcomas (mixed Mullerian tumours): an immunohistochemical study. J Clin Pathol 1997;50:328-331. (Pubitemid 27208253)
27. Huang GS, Arend RC, Li M, et al. Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma. Am J Obstet Gynecol 2009;200:457. e1-457.e5.
28. Ioffe YJ, Li AJ, Walsh CS, et al. Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles. Gynecol Oncol 2009;115:466-471.
29. Jazaeri AA, Nunes KJ, Dalton MS, et al. Welldifferentiated endometrial adenocarcinomas and poorly differentiated mixed Mullerian tumors have altered ER and PR isoform expression. Oncogene 2001;20:6965-6969. (Pubitemid 33052187)
30. Jongen VH, Briet JM, de Jong RA, et al. Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer. Int J Gynecol Cancer 2009;19:670-676.
31. Shabani N, Kuhn C, Kunze S, et al. Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer 2007;43:2434-2444. (Pubitemid 350001248)
32. Catasus L, Machin P, Matias-Guiu X, et al. Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases. Hum Pathol 1998;29:1160-1164. (Pubitemid 28467540)
33. Karamurzin Y, Rutgers JK. DNA mismatch repair deficiency in endometrial carcinoma. Int J Gynecol Pathol 2009;28:239-255.
34. Arabi H, Guan H, Kumar S, et al. Impact of microsatellite instability (MSI) on survival in high grade endometrial carcinoma. Gynecol Oncol 2009;113: 153-158.
35. Amant F, Dorfling CM, Dreyer L, et al. Microsatellite instability in uterine sarcomas. Int J Gynecol Cancer 2001;11:218-223. (Pubitemid 32624385)
36. Bilbao C, Rodriguez G, Ramirez R, et al. The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer. Int J Cancer 2006;119:563-570. (Pubitemid 43955709)
37. Risinger JI, Hayes K, Maxwell GL, et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 1998;4:3005-3010. (Pubitemid 29001474)
38. Amant F, de la Rey M, Dorfling CM, et al. PTEN mutations in uterine sarcomas. Gynecol Oncol 2002;85:165-169. (Pubitemid 34304028)
39. Lee SJ, Kim HS, Kim HS, et al. Immunohistochemical study of DNA topoisomerase I, p53, and Ki-67 in uterine carcinosarcomas. Hum Pathol 2007;38: 1226-1231. (Pubitemid 47058160)
40. Kurihara S, Oda Y, Ohishi Y, et al. Coincident expression of beta-catenin and cyclin D1 in endometrial stromal tumors and related high-grade sarcomas. Mod Pathol 2010;23:225-234.
41. Ng TL, Gown AM, Barry TS, et al. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 2005;18:68-74. (Pubitemid 40128097)
42. Sreenan JJ, Hart WR. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol 1995;19:666-674.